Michael Martino has extensive experience in the life sciences spanning a 35-year career. He is currently acting-CEO of HemaFlo Therapeutics, a small San Diego-based start-up developing a novel therapy for Acute Kidney Injury. Concurrently, he is an advisor to two companies: Excision Biotherapeutics, a New Jersey-based company applying its proprietary gene editing technology to infectious diseases, and SofMat, LTD, a UK-based company applying its proprietary micro-scale 3D surface structure technology to ensure the supply chain security and authenticity of critical, high-value products like pharmaceuticals, semi-conductors and watches. Mike also currently sits on the Board of Trustees of Roanoke College, his alma mater. His skill set focuses on strategy development, team building, operations, business development and raising capital.
Martino joined the board of Ferghana Special Situations Fund (FSSF) as a founding member in 2017.
Prior to HemaFlow, from November 2011 to November 2014 Martino was President and CEO of Ambit Biosciences, a San Diego-based company developing a drug to treat Acute Myeloid Leukemia. Over those three years under Mike’s leadership, the Ambit team initiated a large, multi-national Phase 3 study, recapitalized the company with a $25 million private financing, successfully completed a $90 million IPO, and ultimately sold the company to a large, Japanese pharmaceutical company for $450 million in cash plus future milestone payments. Prior to Ambit, Martino was President and CEO of Sonus Pharmaceuticals, a publicly-traded drug development company located in Bothell, WA that he re-directed to the oncology space, and ultimately raised nearly $200 million in equity financings and collaborative corporate development agreements. Mike’s career started with Mallinckrodt where he enjoyed a 17-year career with over 20 discreet assignments in planning, business development and marketing, including an ex-pat assignment in The Netherlands and an extended assignment in Japan, and culminating with his appointment as VP & General Manager of the company’s Nuclear Medicine business. Additionally, Mike served as initial CEO on the team that in 2008 founded Arzeda, a synthetic biology company, and he remained on the Board thru completion of the company’s Series A financing in 2017.
Mike has a BBA from Roanoke College, and a MBA from Virginia Tech. He has two grown sons, both of whom reside in WA-state. Mike and his wife, Andrea, have resided in San Diego since March 2010. He is a prior Chair of the Board of the Washington Biotechnology & Biomedical Association (WBBA) and well as a prior member of the Board of Trustees of Cascadia Community College, both in Seattle.